Opportunity Information: Apply for PAR 07 184
Apply for PAR 07 184
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Innovative Therapies and Clinical Studies for Screenable Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173 Research Related to Deafness and Communication Disorders 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Dec 15, 2006.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public housing authorities/Indian housing authorities Private institutions of higher education Small businesses Special district governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Native American tribal organizations (other than Federally recognized tribal governments).
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith based or community based organizations can apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Innovative Therapies and Clinical Studies for Screenable Disorders (R01) funding opportunity (PAR 07-184) is an NIH research grant solicitation led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in partnership with the National Institute on Deafness and Other Communication Disorders (NIDCD) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Its central goal is to move the field toward effective treatments for disorders that are already part of newborn screening panels, as well as select genetic conditions that could realistically become screenable in the near future if meaningful therapies are available. The announcement frames a "high priority" condition in practical terms: a disorder where having an efficacious therapy would be the key step that makes newborn screening worthwhile and actionable, because screening is most valuable when an early diagnosis can directly trigger an intervention that improves outcomes.
The FOA uses the NIH Research Project Grant (R01) mechanism, meaning it is intended for substantial, hypothesis-driven research projects that can include basic research, translational work, and clinical studies aimed at developing or testing therapeutic interventions. The scientific scope is shared with two companion announcements that support the same kinds of research but at different scales: an R03 small grant option (PAR 06-341) and an R21 exploratory/developmental option (PAR 06-342). In practice, the R01 track is the appropriate fit for more mature projects that require a larger budget, longer project period, or a more comprehensive study plan than what is typically feasible under an R03 or R21.
Budget size, project duration, and the number of awards are not fixed in advance. NIH indicates that awards will vary depending on what applicants propose and what is justified, and that the final totals will depend on the volume and quality of applications received, along with their requested costs and timelines. There is no cost sharing or matching requirement, which is consistent with most NIH research project grants and reduces barriers for applicants that might not have access to non-federal matching funds.
Eligibility is broad and intentionally inclusive. Eligible applicants include public and private institutions of higher education; nonprofit organizations both with and without 501(c)(3) status; small businesses and other for-profit organizations; state and local governments; U.S. territories and possessions; Native American tribal governments (both federally recognized and other than federally recognized) and tribally designated organizations; regional organizations; and other eligible entities, including faith-based and community-based organizations. Foreign (non-U.S.) organizations are also eligible to apply, and eligible federal agencies may apply as well. The FOA explicitly recognizes and includes institutions that serve historically underrepresented populations, such as Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian Serving Institutions.
From an administrative standpoint, the opportunity is categorized as a discretionary grant within NIH's health-related research portfolio and is tied to multiple CFDA numbers reflecting the participating institutes and their missions, including research related to deafness and communication disorders (93.173), diabetes/digestive/kidney diseases extramural research (93.847), and child health and human development extramural research (93.865). The original posting date was December 15, 2006, and the announcement used multiple receipt dates rather than a single deadline, directing applicants to the full FOA for the specific submission schedule. The listing indicates the FOA was later archived (archive date December 6, 2009), which is important for applicants reviewing it today, since it means the specific announcement is no longer active even though similar program areas may continue under newer FOAs.
Overall, the opportunity is aimed at strengthening the pipeline from disease understanding to real-world treatment options for conditions where early detection through newborn screening can change the clinical trajectory. The NIH emphasis is not simply on screening technology, but on the therapeutic and clinical evidence needed to make screening meaningful: treatments that can be delivered early, studies that establish benefit, and research that supports the translation of genetic and metabolic findings into interventions that improve health outcomes for infants and children.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled Innovative Therapies and Clinical Studies for Screenable Disorders (R01) and is identified as PAR 07-184.
Which NIH Institute is leading this opportunity?
This solicitation is led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Are other NIH Institutes involved?
Yes. NICHD partnered with the National Institute on Deafness and Other Communication Disorders (NIDCD) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What is the central goal of the program?
The central goal is to move the field toward effective treatments for disorders that are already included in newborn screening panels, as well as select genetic conditions that could realistically become screenable in the near future if meaningful therapies exist.
What kinds of disorders does the FOA focus on?
It focuses on (1) disorders currently on newborn screening panels and (2) select genetic conditions that could plausibly become screenable soon, especially if the availability of effective therapy would make screening worthwhile and actionable.
How does the FOA define a "high priority" condition?
A "high priority" condition is described in practical terms: a disorder where having an efficacious therapy would be the key step that makes newborn screening worthwhile because early diagnosis would directly trigger an intervention that improves outcomes.
What funding mechanism does this announcement use?
It uses the NIH Research Project Grant (R01) mechanism.
What type of projects is the R01 meant to support in this program area?
The R01 mechanism is intended for substantial, hypothesis-driven research projects. Under this FOA, that can include basic research, translational work, and clinical studies aimed at developing or testing therapeutic interventions for relevant screenable disorders.
How is this R01 FOA related to other NIH announcements?
The scientific scope is shared with two companion announcements supporting similar research at different scales: an R03 small grant option (PAR 06-341) and an R21 exploratory/developmental option (PAR 06-342).
When is the R01 track typically the best fit compared to R03 or R21?
Based on the description, the R01 track is positioned for more mature projects that require a larger budget, a longer project period, or a more comprehensive study plan than what is usually feasible under an R03 or R21.
Are budget size and project duration fixed?
No. The FOA indicates that budget size, project duration, and the number of awards are not fixed in advance and may vary depending on what applicants propose and what is justified.
How does NIH decide how many awards to make and at what funding levels?
The total awards and amounts depend on the volume and quality of applications received, along with the requested costs and proposed timelines.
Is there a cost sharing or matching requirement?
No. The FOA states there is no cost sharing or matching requirement.
What types of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); small businesses and other for-profit organizations; state and local governments; U.S. territories and possessions; Native American tribal governments (federally recognized and other than federally recognized) and tribally designated organizations; regional organizations; and other eligible entities including faith-based and community-based organizations.
Are foreign (non-U.S.) organizations eligible?
Yes. The FOA indicates that foreign organizations are eligible to apply.
Can federal agencies apply?
Yes. The FOA notes that eligible federal agencies may apply.
Does the FOA specifically encourage or include institutions serving underrepresented populations?
Yes. The FOA explicitly recognizes institutions that serve historically underrepresented populations, including Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian Serving Institutions.
What kind of grant category is this described as?
It is categorized as a discretionary grant within NIH's health-related research portfolio.
Are there CFDA numbers associated with this opportunity?
Yes. The opportunity references multiple CFDA numbers reflecting participating institute missions, including 93.173 (deafness and communication disorders), 93.847 (diabetes/digestive/kidney diseases extramural research), and 93.865 (child health and human development extramural research).
When was the FOA originally posted?
The original posting date listed is December 15, 2006.
Does this FOA have a single application deadline?
No. The announcement used multiple receipt dates rather than a single deadline and directed applicants to the full FOA for the submission schedule.
Is this funding announcement still active?
No. The listing indicates the FOA was archived, with an archive date of December 6, 2009. That means this specific announcement is no longer active, even if similar program areas may continue under newer NIH opportunities.
What is the program emphasizing: screening technology or therapies?
The emphasis is not simply on screening technology. The FOA stresses the therapeutic and clinical evidence needed to make screening meaningful, including treatments that can be delivered early, studies that establish benefit, and research that supports translating genetic and metabolic findings into interventions that improve outcomes for infants and children.
Why does this program link therapies to newborn screening?
Because newborn screening is most valuable when early diagnosis leads to an intervention that improves outcomes. The FOA frames effective therapy as the critical factor that can make screening actionable and clinically worthwhile.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Diet, Epigenetic Events, and Cancer Prevention (R01)
Previous opportunity: Pathogenesis And Treatment Of Lymphedema And Lymphatic Diseases (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 07 184
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 07 184) also looked into and applied for these:
| Funding Opportunity |
|---|
| Vulvodynia Systematic Epidemiologic, Etiologic Or Therapeutic Studies (R01) Apply for PA 07 182 Funding Number: PA 07 182 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Eating Disorders (R01) Apply for PA 07 285 Funding Number: PA 07 285 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R01) Apply for PA 07 219 Funding Number: PA 07 219 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Fragile X Pre mutation and Ovarian Function (R03) Apply for PA 07 220 Funding Number: PA 07 220 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Multidisciplinary Translational Research in Critical Care (R01) Apply for PA 07 233 Funding Number: PA 07 233 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| International Extramural Associates Research Development Awards (IEARDA) (G11) Apply for PAR 07 431 Funding Number: PAR 07 431 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Interdisciplinary Research on Implantation (R01) Apply for PA 07 445 Funding Number: PA 07 445 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) Apply for PAR 07 446 Funding Number: PAR 07 446 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R03) Apply for PAR 07 447 Funding Number: PAR 07 447 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R01) Apply for PA 08 059 Funding Number: PA 08 059 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Role of Adipose Tissue as an Endocrine Organ in Reproduction and Infertility (R21) Apply for PA 08 060 Funding Number: PA 08 060 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Extramural Associates Research Development Award (EARDA) (G11) Apply for PAR 08 096 Funding Number: PAR 08 096 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R01) Apply for PA 08 099 Funding Number: PA 08 099 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Mechanisms of Functional Recovery After Stroke (R21) Apply for PA 08 100 Funding Number: PA 08 100 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Leiomyomata Uteri Basic Science, Translational and Clinical Research (R01) Apply for PAR 08 102 Funding Number: PAR 08 102 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Adverse Outcomes of Assisted Reproductive Technologies (R01) Apply for PA 08 104 Funding Number: PA 08 104 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Investigations on Primary Immunodeficiency Diseases (R01) Apply for PAR 08 206 Funding Number: PAR 08 206 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biosocial Approaches to Infertility Research (R21) Apply for PA 09 032 Funding Number: PA 09 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Womens Reproductive Health Research (WRHR) Career Development Program (K12) Apply for RFA HD 08 014 Funding Number: RFA HD 08 014 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $440,000 |
| Population Research Infrastructure Program Short term Support for Rising Programs (R24) Apply for PAR 07 401 Funding Number: PAR 07 401 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 184", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.